With great interest we read the article of Nishihori et al., 1 in which the authors describe a patient with concurrent multiple myeloma (MM) and myelodysplastic syndrome (MDS), who achieved remission of both malignancies after allogeneic stem cell transplantation (allo-HSCT). We agree with the authors that therapeutic decision-making becomes complex when two hematological disorders are diagnosed in the same patient. This situation becomes even more complex if relapse of one or both entities occurs. To collect further experience and to help clinicians in this decision process, we here describe a patient with relapse of therapy-related MDS (tMDS) after allo-HSCT in the presence of persisting MM.
A 43-year-old male was diagnosed with IgG myeloma Salmon and Durie stage IIIA in January 1999. Four cycles of idarubicine, dexamethasone and cyclophosphamide followed by high-dose melphalan and autologous transplantation in July 1999 resulted in PR of MM. During maintenance therapy with thalidomide followed by interferon alpha starting in October 1999, MM was in continuous PR as indicated by paraproteinemia without new organ damage or need for additional therapy. In July 2005, diagnosis of tMDS (RAEB-I, 8% blasts, IPSS int-2) with complex karyotype (45,XY,del(5)(q22q33),-7,del(12p), add(17)(p11),del(20) (q11),46XY[12]) was made. Therefore, allo-HSCT using PBSC from a fully matched (10/10), unrelated male donor was performed after sequential FLAMSA-Mel-ATG conditioning leading to CR of tMDS and 100% donor chimerism. However, immunofixation and electrophoresis still indicated active myeloma despite acute GvHD (Figure 1 ). One year later, in September 2006, hematological relapse of tMDS (8% BM blasts, complex karyotype) occurred. The patient received four cycles of 5-Aza (100 mg/m 2 per day for 5 days, every 4 weeks) and three DLI (1, 5 and 10 × 10 6 CD3+ cells/kg) reaching CR of tMDS and 100% donor chimerism 2 months after the start of therapy. At that time, myeloma parameters still indicated active disease. Subsequently, the patient developed acute cutaneous and hepatic GvHD, which turned into moderate-to-severe mucocutaneous chronic GvHD. One year after starting 5-Aza (September 2007), CR of MM indicated by negative immunofixation was achieved without additional therapy, while moderate chronic GvHD was still active. More than 6 years after the first relapse, in February 2013, the patient presented with increasing abdominal girth and pain. Gastroscopy revealed several gastric and duodenal tumors and computed tomography (CT) scan showed a large abdominal mass (12 × 10 cm) accompanied by ascites as well as a mediastinal tumor (2.4 cm). Histological analysis of a gastric biopsy showed CD34+/MPO+ myeloid blasts. No evidence of intramedullary relapse of tMDS was found by cytomorphology, cytogenetics (46, XY) and STR-based chimerism (100% donor chimerism). In addition, electrophoresis and immunofixation confirmed ongoing remission of MM. Thus, our patient suffered from isolated extramedullary relapse with several chloromas 75 months after Aza-induced remission of tMDS. Following two cycles of high-dose cytarabine-based chemotherapy, he achieved remission of the myeloid extramedullary manifestations as confirmed by a positron emission tomography-CT scan and by return of WT1 mRNA expression below the normal threshold. After one bridging cycle of Aza, he received second allo-HSCT from an alternative matched unrelated donor (10/10) following conditioning with fludarabine, treosulfan and ATG. No severe complications and GvHD occurred. In January 2013, the patient relapsed with overt AML and finally died while being still in remission with regard to MM.
Although case reports like this or the one from Nishihori et al. never allow definitive conclusions, they often address important issues, which might have an impact beyond the individual case. First, patients with MM are at risk of the development of therapy-related AML (tAML) or tMDS.
2 Furthermore, along with the life-prolonging benefit of novel agents for the treatment of MM, the incidence of tMDS/tAML is likely to rise. In addition, some novel agents like lenalidomide are believed to have the potential to induce secondary malignancies. 3 As a consequence, the number of potential allogeneic transplant candidates may increase. So far, studies on allo-HSCT for patients with tMDS/ AML also included MM patients, but gave no detailed information about the status and course of MM after transplant. A recent report on 21 patients with MDS and concurrent lymphoid malignancies as well as the case of Nishihori et al.
1 demonstrate that cure of both diseases is possible. 4 Still, owing to the different biologic behavior of advanced MM and tMDS/tAML, a substantial proportion of patients suffered from MDS relapse and/or had persistent/relapsing lymphoid malignancy. This also applied to our patient, whose tMDS relapsed within 1 year after allo-HSCT in the presence of persisting MM. In this complex situation, we were able to re-induce long-lasting remission of tMDS by Aza and DLI, which has proven to be an effective salvage therapy for relapse after allo-HSCT. 5, 6 Of interest, DLI and potentially Aza were also able to induce a graft-versus-myeloma-effect resulting in first CR of MM 1 year after remission of tMDS. The time needed to achieve CR of MM in our patient may be an indicator for different GvL/graft versus myeloma kinetics in myeloma in contrast to myeloid malignancies. As DLI alone has the potential to restore remissions in MM, the impact of Aza cannot be definitively ascertained. 7 Nevertheless, it is worth mentioning that Aza can induce re-expression of cancer-testis Ag (CTA) also on myeloma cells. This mechanism is considered to be an important mechanism for GvL reactions by rendering myeloid cells more susceptible to elimination by donor immune cells. 8 In addition, Aza also contributed to remission induction in a patient with another lymphoplasmocytic disorder (Waldenstrom disease) in the presence of MDS. 9 Taken together, in accordance with the report of Nishihori et al.,
1 our case illustrates a group of patients with two hematological disorders such as MM and tMDS, that might be referred more often to transplant centers in the future. It also shows that Aza is an effective alternative for the treatment of myeloid diseases relapsing after allo-HSCT possibly mediating its effects by CTA re-expression. This mechanism might also be active and worth investigating in non-myeloid diseases such as MM.
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